Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 16/20 | 1.00 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.68 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nitric Acid SCHEMBL9845213 | 0.90 | CYP19A1 (0.81) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| SCHEMBL1041969 | 0.86 | CYP19A1 (0.76) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| SCHEMBL1912921 | 0.85 | CYP19A1 (0.74) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| SCHEMBL2142550 | 0.85 | CYP19A1 (0.74) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| SCHEMBL2354499 | 0.85 | CYP19A1 (1.00) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| SCHEMBL14769100 | 0.84 | CYP19A1 (0.73) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| SCHEMBL2351179 | 0.84 | CYP19A1 (0.73) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| Hydrochloric Acid SCHEMBL9260352 | 0.84 | CYP19A1 (1.00) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| SCHEMBL2354504 | 0.82 | CYP19A1 (0.70) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| Fadrozole SCHEMBL25491 | 0.81 | CYP19A1 (1.00) | CYP19A1CYP11B2CYP11B1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5583128-A | ADMINISTERING A SIDE EFFECT REDUCED AROMATASE INHIBITOR | CIBA-GEIGY CORPORATION (US) | 1996-12-10 | — | — | US | claimed |
| EP-0165904-B1 | SUBSTITUTED BICYCLE COMPOUNDS | CIBA-GEIGY AG (CH) | 1991-04-10 | — | — | EP | claimed |
| US-4617307-A | Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors | CIBA-GEIGY CORPORATION (US) | 1986-10-14 | — | — | US | claimed |
| EP-0165904-A2 | Substituted bicycle compounds | CIBA-GEIGY AG (CH) | 1985-12-27 | — | — | EP | claimed |
| US-12590950-B2 | Methods for predicting ER-mediated DNA damage | UNIVERSITY OF MASSACHUSETTS (US) | 2026-03-31 | — | — | US | disclosed |
| US-20210109085-A1 | METHODS FOR PREDICTING ER-MEDIATED DNA DAMAGE | UNIVERSITY OF MASSACHUSETTS | 2021-04-15 | — | — | US | disclosed |
| US-9278969-B2 | Organic compounds | NOVARTIS AG (CH) | 2016-03-08 | — | — | US | disclosed |
| US-9278969-B2 | Organic compounds | NOVARTIS AG (CH) | 2016-03-08 | — | — | US | disclosed |
| US-9278969-B2 | Organic compounds | NOVARTIS AG (CH) | 2016-03-08 | — | — | US | disclosed |
| US-20140357621-A1 | Organic Compounds | NOVARTIS AG (CH) | 2014-12-04 | — | — | US | disclosed |
| US-20140357621-A1 | Organic Compounds | NOVARTIS AG (CH) | 2014-12-04 | — | — | US | disclosed |
| US-20140357621-A1 | Organic Compounds | NOVARTIS AG (CH) | 2014-12-04 | — | — | US | disclosed |
| EP-0366609-B1 | Use of bicyclic imidazole derivatives in treating hyperaldosteronism | CIBA GEIGY AG (CH) | 1994-04-27 | — | — | EP | disclosed |
| US-5057521-A | USE OF BICYCLIC IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HYPERALDOSTERONISM | CIBA-GEIGY CORPORATION (US) | 1991-10-15 | — | — | US | disclosed |
| EP-0165904-B1 | SUBSTITUTED BICYCLE COMPOUNDS | CIBA-GEIGY AG (CH) | 1991-04-10 | — | — | EP | disclosed |
| EP-0366609-A2 | Use of bicyclic imidazole derivatives in treating hyperaldosteronism | CIBA-GEIGY AG (CH) | 1990-05-02 | — | — | EP | disclosed |
| US-4889861-A | Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors | CIBA-GEIGY CORP. (US) | 1989-12-26 | — | — | US | disclosed |
| US-4728645-A | THROMBOXANE SYNTHETASE INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1988-03-01 | — | — | US | disclosed |
| US-4617307-A | Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors | CIBA-GEIGY CORPORATION (US) | 1986-10-14 | — | — | US | disclosed |
| EP-0165904-A2 | Substituted bicycle compounds | CIBA-GEIGY AG (CH) | 1985-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140357621-A1 | Organic Compounds | CYP19A1, CYP17A1, HSD17B11 | CYP19A1 1/4885CYP11B2 14/4885CYP11B1 5/4885 |
| US-12590950-B2 | Methods for predicting ER-mediated DNA damage | ESR1, ESR2, ESRRA | CYP19A1 7/4885CYP11B2 399/4885CYP11B1 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.